Back to search results

GLP-1 RAs and Breastfeeding Study

This observational study is looking at how medications like semaglutide and tirzepatide (called GLP-1 Receptor Agonists, or GLP-1 RAs) affect breast milk production and its nutritional content. These medications are often used for weight loss after pregnancy. Researchers want to know if these drugs increase or decrease how much milk you make, and if they change the fat content or other nutrients in your milk. You could join if you are a breastfeeding mother, remove milk at least four times a day, and are already eligible for an injected GLP-1 RA from your doctor. The study will measure your milk production and composition before and after you start taking the medication. This study is currently unclear on its recruitment status and plans to enroll 18 participants.

Study design
This is an observational study, meaning researchers will watch what happens when you take GLP-1 RA medications prescribed by your doctor. It plans to include 18 participants.
What's involved
You will weigh yourself and report measurements daily. You will also participate in 2-3 morning study visits and provide 1-3 ounces of breast milk per visit.
Compensation
Not stated in the trial record.
Follow-up
Your milk production and composition will be measured from one week before until a maximum of 2 months after beginning GLP-1 RA treatment. This timeframe will restart if your dosage is increased.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07720414

Effects of GLP-1 RAs on Human Lactation Outcomes

Recruiting
Not specifiedAll AgesObservational
University of Colorado, Denver
~18 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:Injected GLP-1 Receptor Agonists and Dual Agonists

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hourly milk production rate
Measured over From one week before until a maximum of 2 months after beginning GLP-1RA treatment. This timeframe will restart if their dosage is increased.
+1 more outcome measured

Conditions

Lactation
Weight Loss

Explore related trials

Weaning

Where it's being run

1 sites across 1 states
Colorado1

Who to contact

Jayne F Martin Carli, PhD
[email protected]
303-724-3981
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Breastfeeding mothers of single or multiple infants.
Milk removal at least 4x daily
Eligible for a GLP-1 RA administered subcutaneously (oral GLP-1 RAs contain absorption enhancers, which may drive accumulation in milk)
Access to a breastpump, if needed for maintaining breastfeeding behaviors.
Willingness to provide 1-3 oz of breastmilk per study visit.
Willingness to track and report body weight daily.
Willingness to maintain breastfeeding behaviors for the duration of the study.

Exclusion

Currently taking GLP-1 RA medication or other weight loss medication
Induced lactation, due to unknowns regarding the durability of the mammary gland's milk production after exogenous stimulation.

What this trial measures

  • Hourly milk production rateFrom one week before until a maximum of 2 months after beginning GLP-1RA treatment. This timeframe will restart if their dosage is increased.

    Milk production rate (in grams per hour) will be assessed using a standardized milk expression protocol.

  • Milk macronutrient compositionFrom one week before until a maximum of 2 months after beginning GLP-1RA treatment. This timeframe will restart if the dosage is increased.

    Milk macronutrient composition will be assessed using the Miris Human Milk Analyzer.